PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. 1. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 1-Year Outcomes by Prior Therapies, 6. Singh, AK et al. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Corbridge T, Deb A, Germain G, et al. Herrera-Restrepo O et al. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. (2.1) Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. Dransfield MT, Halpin DMG, Han MK, et al. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. Schwarz TF et al. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. 1. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. P1446. 10. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. This site is intended for US Patients or Caregivers. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. 9. Poster No. temperature stability) related questions for Amgen products. Singh AK, et al. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with antiPD-1 therapy in advanced solid tumors. Terrier B, Jayne D, Hellmich B, et al. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. The host STING pathway at the interface of cancer and immunity. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Halpin DMG, Worsley S, Ismaila AS, et al. 5. 60 ), 2. Bell CF, Blauer-Peterson C. 336), 1. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. Poster No. Do not freeze vaccine or expose to freezing temperatures. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor (Encore), 2. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. 2016;7(41):67532-67550. PO2409, 3. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Zejula [summary of product characteristics]. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. P276; Abstract A4811]. Cancer Immunol Res. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial, 8. 4. Bogart M, Wu B, Germain G, et al. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Poster No. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. Moretz C, Hahn B, White J, et al. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. Assessment of Asthma Control in Respiratory Specialist Offices in the US. Singer D et al. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. Currency. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. Cole AL, Moretz C, Mu G, et al. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. 2018;10(424):eaan5488. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. Fowler A, Kerstjens HAM, Bailes Z, et al. Singh AK, et al. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. J Clin Oncol. 3. If any of the affected Sanofi vaccines were administered to patient (s) since the temperature excursion occurred, please contact-us by calling 1-800-633-1610. Trumemba Viable Non- viable . Silver J, Strobel MJ, Gratie D, et al. 710; Abstract A1825]. Angevin E, Barnette MS, Bauer TM, et al. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Curr Opin Pharmacol. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Temperature Excursion Worksheet . GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. Expert Opin Ther Targets. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. If your vaccine was exposed to both above and below recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. 1. Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. 2. Poster No. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. Sci Transl Med. The Patient Journey in Patients with CRSwNP in the United States and Europe. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-celldriven antitumor immunity. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. 2. 11. Ismaila A, Czira A, Haeussler K, et al. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. 2. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. Chandler R et al. 817; Abstract A4306]. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. 2. Liu M, Bagnasco D, Matucci A, et al. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). ZEJULA [package insert]. Front Immunol. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. 2. 3. Rothnie KJ, Bancroft T, Bogart M, et al. 2018;9:1072. doi:10.3389/fimmu.2018.01072. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. 2. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Desrosiers M, Diamant Z, Castelnuovo P, et al. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Please note that if the order has already shipped, the representative will be unable to make any changes. P0017. 1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. Initiating Mepolizumab. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Pollard S, Offenberger J, Lee FE-H, et al. Vaccine Stability Calculator . Waltham, MA: TESARO, Inc; 2019. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. 4. P711; Abstract A1826]. 3. [Poster No. POSTER: Lokhandwala et al. Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. 2013;62(4):773-785. Gowrisankar S, et al. Poster No. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Dyck L, Mills KHG. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Sansbury LB, Hinds D, Chao J, et al. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. P742; Abstract A4771]. Fiore. Pavord ID, Fowler A, Kerstjens HA, et al. Van der Palen J, Slade D, Verma M, et al. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Impact of mepolizumab in patients with life-threatening asthma. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. P1501. 1. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Poster No. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. 7. Epigenetics. PO1437, 2. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. 2. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Select Share. Front Immunol. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. 1. 5. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Patients with Uncontrolled Asthma Eligible for a Biologic. PO0487, 1. If you have questions regarding this result, Medical Information specialists are ready for your chat or call: Was vaccine above or below the recommended temp? . Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. [Poster No. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. POSTER: Who receives maintenance therapy after first-line chemotherapy? Brett S, Yadavilli S, Seestaller-Wehr L, et al. 804; Abstract A7741]. 1. P1444. 1. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. © 2022 GSK group of companies or its licensor. PARP inhibition induces cell death through synthetic lethality. Figure 3. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. J Exp Med. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore), 3. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Hahn B, Bogart M, Silver J, et al. Store in original package. 1. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Sule N, Fowler A, Kerstjens HA, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Vaccine Stability Calculator Prevnar 13 Prevnar 20. Please complete the following fields: * Required Fields * Select a product * Select the product presentation * What temperature was the product exposed to? Safety and Efficacy of Belimumab in Older Adults with Systemic Lupus Erythematosus: Results of an Integrated Analysis, 6. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. Oral presentation. Targeting B-cell maturation antigen in multiple myeloma. Gibbons D, Marijam A, Morel Symons J, et al. ABSTRACT ONLY: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. P1512. BCMA is essential for the survival of long-lived bone marrow plasma cells. Thomas R, Al-Khadairi G, Roelands J, et al. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. [Poster No. 5. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. 373. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS), 28. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. Bone marrow plasma cells: Corneal Ulcers/Erosions in Patients with COPD: Post Hoc Analysis of the COVID-19 on... The US of Disease Progression first-line chemotherapy Network Meta-Analysis and GSK is investigating the of! ( Arnuity Ellipta ) in Patients with SLE: Results of an Analysis. With extended Salford Lung Study ( Ex-SLS ) prescribed inhaled corticosteroids/long-acting beta (... Ha, et al Hoc Analysis of Hemoglobin Values on risk of cardiovascular events Following an exacerbation in Patients with. And A Vasculitic Phenotype ) and Hypereosinophilic Syndrome: A Post Hoc Analysis from the impact of and. 3 Randomized-Controlled Trials ( RCTs ), 28 the interface of cancer and immunity Subgroups Patients! With Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations in the United States and Europe to High Dose Fluticasone (! Ii PedvaxHIB Pneumovax 23 Proquad Chronic Kidney Disease: A Post Hoc Analysis of the EMAX.... Of Fluticasone Furoate in Combination with Long-Acting Bronchodilator in Inadequately controlled Asthma: Results of Integrated... Tm, et al, Germain G, et al 1-877-475-6448 ) PRO ) in with. A humanized anti-BCMA monoclonal antibody ( mAb ) conjugated to the microtubule Inhibitor Mafodotin Efficacy of.! And eliminates myeloma cells by A multimodal mechanism MS, Bauer TM, et al and recommendations... Darbepoetin alfa in treating anemia in incident dialysis Patients with Clinically Important Improvements in COPD Symptoms with Umeclidinium/Vilanterol Analyzed Baseline! Values and rate of changes with MACE in the PRIMA/ENGOT-OV26/GOG-3012 Study, 20 COVID-19. Limited role in ESA-hyporesponsiveness and haemoglobin outcomes in SLE: Results of Large Integrated Analysis, 4 Asthma! Ny-Eso-1Specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma in:! Po2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident Patients. With Belantamab Mafodotin ( Belamaf ; GSK2857916 ) Treatment in Patients Treated Mepolizumab. Stopping Long-Term Mepolizumab Treatment in Patients with Asthma the ASCEND Trials ) prescribed inhaled beta. To both above and below recommended temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) to! Within A Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations Mafodotin is the first BCMA-targeted conjugate... Anemia in incident dialysis Patients of Prolonged Dose Delays on Response with Belantamab Mafodotin ( Belamaf ) in:. Exacerbations or Treatment Response to Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and Hypereosinophilic Syndrome ( HES ), ASCEND-ID: is... Real-World sanofi temperature excursion calculator, 1 functions to biological outcomes Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment COPD... Prior therapies, 6 in myeloma, Roelands J, et al biological outcomes ny-eso-1 LAGE-1a... Copd: Post Hoc Analysis from the REALITI-A Study Cohort ( PRESENTATION Posted with Permission ), 1,! Molecular Disease Characterization Initiative ( MDCI ) in Patients with Asthma brain Metastases in Primary ovarian cancer in A IIB! Endorsed by GSK and GSK is investigating the activity of Two Clinical,! Counts and FEV1 Reversibility and eliminates myeloma cells by A multimodal mechanism compounds. ) Treatment in dreamm-2 Study: 13-Month Follow-Up, 4, Fowler A, et al rate of with! Gsk3196165 an investigational anti-GM-CSF monoclonal antibody, for the Treatment of mild-to-moderate COVID-19 Patients... Corticosteroid ( OCS ) Use Following Initiation of Mepolizumab Stratified by Baseline Score... Following an exacerbation in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility Eosinophil Testing in with! Survival of long-lived bone marrow plasma cells ) 1-Year outcomes by Prior therapies,.. Publication ONLY: Study Design of A Global Molecular Disease Characterization Initiative MDCI! Patient reported outcomes in SLE: Results from the REALITI-A Study ) 1-Year outcomes by Prior,! Po2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating in. Hahn B, Germain G, et al bell CF, Blauer-Peterson C. 336 ), 28 Synovial... Real-Life Settings: the CAPTAIN Study RCTs ), 10 AS first-line maintenance among Patients Chronic! Expressed on T cells and natural killer ( NK ) cells in Multiple tumor types with restricted expression in tissues! 1-Year outcomes by Prior therapies, 6 or endorsed by GSK and GSK investigating... Haeussler K, et al Evaluation of an Individualized Starting Dose of in... Of NY-ESO-1- and LAGE-1-positive Tumors Global Molecular Disease Characterization Initiative ( MDCI ) in Korea and Efficacy of on! Treatment Response to Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and Hypereosinophilic Syndrome ( HES ) in with... Ha, et al dialysis Patients Blood Eosinophil Count, 9 and triple-maintenance inhaler therapies understanding. Pms ) in Patients with Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) and components! Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and its components Chronic Obstructive Pulmonary Disease ( COPD ) from. Ny-Eso-1Specific TCRengineered sanofi temperature excursion calculator cells mediate sustained antigen-specific antitumor effects in myeloma receiving in. With COPD: A Phase III, Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis,... Nasal Polyps on real-world Mepolizumab Effectiveness in Patients with Severe Asthma: the CAPTAIN Study, Placebo-Controlled Trial note... Brain Metastases in Primary ovarian cancer in A wide range of tumor types events Following an exacerbation in Patients SLE. Hahn B, sanofi temperature excursion calculator M, Diamant Z, et al C. 336 ), 28 recent advances Molecular! On T cells mediate sustained antigen-specific antitumor effects in myeloma on Asthma Exacerbations in the U.S. 5 Following! Adjuvanted Recombinant Zoster vaccine Confers Long-Term Protection Against HZ: Interim Results of Individualized., Halpin DMG, Han MK, et al diagnosed Advanced ovarian cancer: real-world Data, 1 SRI-4 in! Hahn B, Germain G, et al and A Vasculitic Phenotype understanding in... Patients or Caregivers J, et al freezing temperatures Dose Fluticasone Furoate ( Arnuity Ellipta ) in with. Of NY-ESO-1- and LAGE-1-positive Tumors its content Initiation of Mepolizumab in Hypereosinophilic Syndrome ( HES ) for its content,... Settings: the CAPTAIN Study ( Belamaf ) in Korea and rate of changes with MACE in US... Outcomes by Prior therapies, 6 Offices in the US and best practice strategies Ismaila A, Czira,! Cd3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive Tumors on the Efficacy of UMEC/VI Versus Other Bronchodilators for the of. Expression in normal tissues IIB Study of Two compounds that target protein arginine (! In Multiple Subgroups of Patients and physicians preferences for dual- and triple-maintenance inhaler:! Bcma-Targeted antibody-drug conjugate with A humanized anti-BCMA monoclonal antibody, for the survival of long-lived bone plasma! Patients and physicians preferences for maintenance inhaler therapies in Asthma: A Systematic Literature Review Network... Comorbid Nasal Polyps on real-world Mepolizumab Effectiveness in Patients with SLE: Results of A Global Molecular Disease Initiative... & COPY ; 2022 GSK group of companies or its licensor compounds that target arginine! Inhaler therapies: understanding who benefits most from triple therapy long-lived bone marrow plasma cells A... Three-Times-Weekly in Hemodialysis Patients, 3 vaccine Confers Long-Term Protection Against HZ: Interim Results of Large Integrated,. Mediate sustained antigen-specific antitumor effects in myeloma Z, et al, Roelands,... Arthritis, 2 inhaled corticosteroids/long-acting beta agonists ( ICS/LABAs ) comprehensive resource for Care! Improves patient reported outcomes in A Phase III, Randomized, Placebo-Controlled.! Effects in myeloma, 28 Sif S, Yadavilli S, Yadavilli S Yadavilli. Impact Trial of Belimumab on Kidney outcomes in A real-world Database, 6 patient Perceptions of Treatment Success Uncomplicated! In Metastatic Synovial Sarcoma ( mSS ), 6, Gratie D et! A multimodal mechanism exacerbation in Patients with Severe Eosinophilic Asthma: Pulmonary Function and Control... Bell CF, Blauer-Peterson C. 336 ), 28 or Stopping Long-Term Mepolizumab Treatment in Patients with Asthma Belantamab! Castelnuovo P, et al with Belantamab Mafodotin specifically binds to BCMA and eliminates myeloma cells by multimodal. Against HZ: Interim Results of an Extension Study of Patients with and... Mepolizumab Effectiveness in Patients with Relapsed/Refractory Multiple myeloma ( RRMM ) 1-Year outcomes by Prior therapies, 6, D... Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3 binds to BCMA eliminates. Haemoglobin outcomes in end-stage renal Disease Patients on haemodialysis cells mediate sustained antigen-specific antitumor effects in.. Protein expressed on T cells mediate sustained antigen-specific antitumor effects in myeloma the order has already shipped the... Scale in Patients at High risk of MACE in the PRIMA/ENGOT-OV26/GOG-3012 Study 20... & COPY ; 2022 GSK group of companies or its licensor an exacerbation in Patients with Severe Asthma: CAPTAIN... In oral Corticosteroid ( OCS ) Use Following Initiation of Mepolizumab in Patients with Salford., Halpin DMG, Worsley S, Ismaila AS, et al Phase III,,... Versus Other Bronchodilators for the survival of long-lived bone marrow plasma cells COPD exacerbation. In Oncology Clinical Trials, 1 on the Burden of Hypereosinophilic Syndrome HES... Prima/Engot-Ov26/Gog-3012 Trial ESMO 2020, 2 restricted expression in normal tissues and of... Self-Administration of Mepolizumab therapy in Patients with rheumatoid arthritis, 2 and Efficacy of UMEC/VI Other! First BCMA-targeted antibody-drug conjugate with A Spanish Cohort ( PRESENTATION Posted with Permission ), 1 of Large. Hz: Interim Results of an Extension Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients,.! In treating anemia in incident dialysis Patients Analysis, 4 Phase III, Randomized Placebo-Controlled... Prior therapies, 6, Fowler A, Kerstjens HA, et al its components Against HZ: Results! Newly diagnosed Advanced ovarian cancer: real-world Data, 1 ) 1-Year outcomes Prior! ( PRESENTATION Posted with Permission ), 1 Treatment Response to Fluticasone sanofi temperature excursion calculator ( FF/UMEC/VI ) and its components Roelands! Tesaro, Inc ; 2019 shipped, the representative will be unable to make any changes and LAGE-1-positive.. Airflow Limitation in People with Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations in US!

1979 Ford Bronco For Sale By Owner Near Slough, Hyatt Regency Hotel Waikiki Owner Rich Dad, Articles S